Assess relevant DNA and RNA cancer biomarkers from FFPE tumor tissue with the added flexibility of automation-friendly kits.
Batch up to 192 samples at a time while using the same panel content and tissue input type as the TruSight Oncology 500 assay.
Analyze liquid biopsies (blood) to assess circulating tumor DNA (ctDNA) with similar DNA panel content as the TruSight Oncology 500 assay.
|Pan-Cancer Biomarkers NTRK1 NTRK2 NTRK3 MSI TMB|
The genes and biomarkers listed in this table are a subset of all genes included in the panel. To see the full gene list, view the product datasheet, available under Product Literature on the respective product pages.
Experts discuss why they decided to implement in-house CGP, share analytical performance data, and provide details about their end-to-end workflow.
Learn critical workflow and bioinformatics considerations when consolidating biomarkers testing into a panel that enables CGP from liquid biopsy samples in clinical trials.
15 European centers participated in this Quality in Pathology (QuIP) study which tested inter-laboratory and inter-platform variation for gene panel vs. whole exome for reliable tissue TMB assessment.
NTRK fusions are rare but important biomarkers linked to response to new TRK inhibitors. Watch CMO Phil Febbo and Maude Champagne walk through these advances in fusion detection.